- Report
- August 2025
- 200 Pages
United States
From €2229EUR$2,490USD£1,947GBP
- Report
- August 2024
- 200 Pages
Global
From €2229EUR$2,490USD£1,947GBP
- Report
- December 2024
- 171 Pages
Global
From €3536EUR$3,950USD£3,088GBP
- Report
- September 2024
- 343 Pages
Global
From €7116EUR$7,950USD£6,216GBP
- Clinical Trials
- April 2025
- 220 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- April 2023
- 115 Pages
Global
From €4252EUR$4,750USD£3,714GBP
- Report
- March 2023
- 147 Pages
Global
From €4430EUR$4,949USD£3,870GBP
- Report
- May 2024
- 133 Pages
Global
From €3580EUR$3,999USD£3,127GBP
- Report
- April 2023
- 117 Pages
Global
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4431EUR$4,950USD£3,870GBP
- Report
- January 2024
- 150 Pages
Global
From €4341EUR$4,850USD£3,792GBP
- Report
- September 2024
- 128 Pages
Global
From €13422EUR$14,995USD£11,724GBP
- Report
- August 2024
- 49 Pages
Global
From €3576EUR$3,995USD£3,124GBP
- Clinical Trials
- December 2023
- 2092 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- January 2023
- 90 Pages
Global
From €3128EUR$3,495USD£2,733GBP
- Report
- May 2023
- 79 Pages
Global
From €3500EUR$4,189USD£3,164GBP
- Report
- May 2023
- 109 Pages
Global
From €3500EUR$4,189USD£3,164GBP
- Report
- January 2025
- 132 Pages
Global
From €850EUR$950USD£743GBP
- Report
- January 2025
- 132 Pages
Global
From €850EUR$950USD£743GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more